Erasca (ERAS) IPO Opens Fractionally Lower

Today's IPO for Erasca, Inc. (NASDAQ: ERAS) opened for trading at $15.90 after pricing 18,750,000 shares of common stock at an initial public offering price of $16.00 per share.

J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering.

At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

You May Also Be Interested In

• BofA sees growing investor reluctance to fund AI infrastructure
• Important Notice to Long-Term Shareholders of Coastal Financial Corporation (NASDAQ: CCB); D-Wave Quantum Inc. (NASDAQ: QBTS); Erasca, Inc. (NASDAQ: ERAS) and Planet Fitness, Inc. (NYSE: PLNT): Grabar
• Micron, Sandisk gain as SK Hynix scraps Solidigm IPO, LYNX says